Sunil Solomon, MD

CRS:

JHU

Role:

Investigators

Position:

Investigator

Sunil Suhas Solomon, MBBS PhD MPH is an Associate Professor of Medicine, in the Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. He is also the Chairman of the YR Gaitonde Medical Educational and Research Foundation, Chennai, India. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Masters in Public Health and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa honors society for academic excellence and the Delta Omega Public Health honors society. His research is focused on the epidemiology, clinical management and access to HIV and HCV care among vulnerable Indian populations such as people who inject drugs and men who have sex with men. He has over 100 peer-reviewed publication in several highly ranked journals such as the Lancet ID, PLOS Medicine, Lancet HIV, Clinical Infectious Diseases, American Journal of Epidemiology, Addiction and AIDS. In 2015, he was one of the first recipients of the Avenir award, a Director’s award from the National Institutes of Health, USA aimed at identifying individuals who propose high impact research and who show promise of being tomorrow's leaders in the field of drug abuse and HIV.

  • Investigator, Hepatitis TSG (Dec 2015-present)
  • Investigator, A5380
  • Chair, A5360

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More